{"symbol": "CGEN", "companyName": "Compugen Ltd", "exchange": "NASDAQ", "industry": "Biological Product (except Diagnostic) Manufacturing ", "website": "www.cgen.com", "description": "Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is expected to enter the clinic in early 2020. The Company's therapeutic pipeline also includes early-stage immuno-oncology programs focused largely on myeloid targets. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with offices in South San Francisco, CA.", "CEO": "", "securityName": "Compugen Ltd", "issueType": "cs", "sector": "Manufacturing", "primarySicCode": 2836, "employees": null, "tags": ["Health Technology", "Biotechnology"], "address": null, "address2": null, "state": null, "city": null, "zip": null, "country": null, "phone": null}